The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form ...

The Light Adjustable Lens (LAL) enables rapid achievement of excellent visual acuity, often reaching 20/25 or 20/20 on the first postoperative day. Patient selection is crucial; detail-oriented ...

Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...

Panelists discuss how trial findings for aflibercept 8 mg and faricimab in RVO demonstrate comparable efficacy and durability ...

Panelists discuss how pivotal RVO trial data for aflibercept 8 mg show strong durability and visual outcomes while raising ...

FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...

Chris R. Alabiad, MD: There wasn’t one single national rule change in 2025 that transformed residency training overnight.

The PRIMA system is a subretinal implant designed to restore central vision in GA patients by replacing failed photoreceptors ...

Ophthalmology conferences are often remembered not just for scientific sessions or new technologies, but for the personal ...

Refractory dry eye in patients with systemic comorbidities can be challenging to manage because the underlying condition or ...

An overview of the top 10 stories from Optometry Times in 2025.

Looking back on 2025, Neda Shamie shares how a challenging monocular patient reinforced the importance of patience, presence, ...